Table 5.

Laboratory findings in typical cases of suppressed/enhanced-fibrinolytic-type DIC and VITT.

Disease		Suppressed-Fibrinolytic-Type DIC	Enhanced-Fibrinolytic-Type DIC	VITT
Underlying disease/cause		Severe sepsis	APL, aortic aneurysm, prostate cancer, etc.	Adenovirus vector type vaccination
Pathophysiology		Activation of coagulation and mild fibrinolysis activation	Activation of coagulation and enhanced fibrinolysis	Antibodies against PF4 are mediated platelet and coagulation activation
Main symptom		Organ damage	Bleeding	Headache, abdominal pain, etc.
Examination findings	Platelet count	Decreased	Decreased	Decreased
	PT	Prolonged	Normal to prolonged	Normal to prolonged *
	APTT	Prolonged	Slightly shortened to prolonged	Normal to prolonged *
	Fibrinogen	Normal to elevated	Decreased	Significantly reduced to normal
	D-dimer	Increased	Increased	Increased
	FDP	Increased	Markedly increased	Increased—markedly increased *
	TAT	Increased	Increased	Increased *
	PIC	Slightly increased	Markedly increased	Increased—markedly increased *
Medical treatment		Anticoagulant therapy	Anticoagulant therapy ± antifibrinolytic therapy	Anticoagulant therapy other than heparin, high-dose immunoglobulin therapy, etc.

* Author’s guess due to insufficient information. Abbreviations: DIC, disseminated intravascular coagulation; VITT, vaccine-induced immune thrombotic thrombocytopenia; APL, acute promyelocytic leukemia; PF4, platelet factor 4; PT, prothrombin time; APTT, activated partial thromboplastin time; FDP, fibrin/fibrinogen degradation products; TAT, thrombin–antithrombin complex; PIC, plasmin–α₂ plasmin inhibitor complex.